Trial Profile
The effect of PPARgamma stimulation on glucose metabolism, insulin resistance, growth hormone and cortisol on women suffering from polycystic ovary syndrome
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Pioglitazone (Primary)
- Indications Polycystic ovary syndrome
- Focus Biomarker; Pharmacodynamics
- 01 Mar 2009 Results from an analysis of secondary endpoints published in Fertility and Sterility.
- 01 Sep 2008 Results published in the Journal of Clinical Endocrinology and Metabolism.
- 01 May 2008 Results have been reported.